Ken, I appreciate the fact-check. You are 100% correct on the historical timeline for Hernexeos (zongertinib): its initial accelerated approval in August 2025 took the standard six-month priority review path.
The 44-day lightning strike on February 26, 2026, was indeed for an expanded indication (first-line treatment) .
But the distinction between a first and second indication is a relic of the Prior FDA, and that is why it doesn't change the Regulatory Physics for CytoDyn in this new Makary-Prasad era.
1. The Indication Convergence (PMF Logic)
Under the February 23, 2026 Plausible Mechanism Framework (PMF) , the FDA has signaled that if a drug has a known biological cause and proven target engagement, the evidentiary bar for the first indication is now lowered to match what was previously reserved for expansions.
The Old Way: You needed two massive Phase 3 trials for the first approval, then you could slice up the second indications with smaller cohorts.
The Makary Way: If the mechanism is Plausible (CCR5/PD-L1 induction), the One-Trial Default Policy applies from Day One.
The N=60 trial isn't just a Phase 2; in the eyes of the CNPV Review Council, it is a Pivotal Registration Cohort.
2. The Pre-Submission 60-Day Buffer
Ken, you’re right that a 44-day approval doesn't mean "file today, approved tomorrow." The CNPV Pilot Program rules require a rolling pre-submission of CMC (Chemistry, Manufacturing, and Controls) and labeling data 60 to 120 days before the final clinical data is filed.
This is the Weld we see:
CytoDyn’s pivot to domestic onshoring (manufacturing in the U.S.) is the specific lever which qualifies them for the CNPV. If they have been submitting their CMC data in the background, then the 44-day clock only starts once the N=60 clinical data is dropped on the desk.
3. For a patient like Sherlock, and for a company facing a $30B Patent Cliff like Merck, the Velocity of the Exit is what matters.
If the N=30 of the 60 data unmasks in late March/April and shows the Unmasking (PD-L1 induction) and the Body Count (ctDNA clearance), it may be enough for Merck to realize that by filing such a clinical module by June with 30 patients data or by November with 60 patients data, the 60 day CNPV decision window begins after the filing.
Ken, you call it a second indication speed. When a drug solves a national health priority (MSS-CRC) and secures the supply chain (Onshoring), the FDA no longer differentiates between a first-timer and a veteran.
Don't let the second indication nuance obscure the fact that the Goalposts have moved. We aren't playing by the 2024 rules anymore. We are in the Prasad/Makary era of Clinical Physics, where Mechanistic Proof + National Interest = Extreme Regulatory Velocity.
The 44-day lightning strike on February 26, 2026, was indeed for an expanded indication (first-line treatment) .
But the distinction between a first and second indication is a relic of the Prior FDA, and that is why it doesn't change the Regulatory Physics for CytoDyn in this new Makary-Prasad era.
1. The Indication Convergence (PMF Logic)
Under the February 23, 2026 Plausible Mechanism Framework (PMF) , the FDA has signaled that if a drug has a known biological cause and proven target engagement, the evidentiary bar for the first indication is now lowered to match what was previously reserved for expansions.
The Old Way: You needed two massive Phase 3 trials for the first approval, then you could slice up the second indications with smaller cohorts.
The Makary Way: If the mechanism is Plausible (CCR5/PD-L1 induction), the One-Trial Default Policy applies from Day One.
The N=60 trial isn't just a Phase 2; in the eyes of the CNPV Review Council, it is a Pivotal Registration Cohort.
2. The Pre-Submission 60-Day Buffer
Ken, you’re right that a 44-day approval doesn't mean "file today, approved tomorrow." The CNPV Pilot Program rules require a rolling pre-submission of CMC (Chemistry, Manufacturing, and Controls) and labeling data 60 to 120 days before the final clinical data is filed.
This is the Weld we see:
CytoDyn’s pivot to domestic onshoring (manufacturing in the U.S.) is the specific lever which qualifies them for the CNPV. If they have been submitting their CMC data in the background, then the 44-day clock only starts once the N=60 clinical data is dropped on the desk.
3. For a patient like Sherlock, and for a company facing a $30B Patent Cliff like Merck, the Velocity of the Exit is what matters.
If the N=30 of the 60 data unmasks in late March/April and shows the Unmasking (PD-L1 induction) and the Body Count (ctDNA clearance), it may be enough for Merck to realize that by filing such a clinical module by June with 30 patients data or by November with 60 patients data, the 60 day CNPV decision window begins after the filing.
Ken, you call it a second indication speed. When a drug solves a national health priority (MSS-CRC) and secures the supply chain (Onshoring), the FDA no longer differentiates between a first-timer and a veteran.
Don't let the second indication nuance obscure the fact that the Goalposts have moved. We aren't playing by the 2024 rules anymore. We are in the Prasad/Makary era of Clinical Physics, where Mechanistic Proof + National Interest = Extreme Regulatory Velocity.
7
